FDA Approves Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Tablets For The Treatment Of HIV Infection

US FDA gave green signal to Symfi Tablets For The Treatment Of HIV Infection

Mylan Pharmaceutical Inc.receives FDA approval for Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) tablets for the treatment of HIV infection.

Company: Mylan Pharmaceutical Inc.

Brand Name: Symfi

Dosage Form: Capsule

Generic Name: efavirenz, lamivudine and tenofovir disoproxil fumarate

Dosage Form: Tablets

Treatment For: HIV Infection

 

 

General information about Symfi

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1(HIV) infection.

 

 

Top